Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 2 000 UNITS AND SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 2 000 UNITS AND SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs MAGNESIUM SULFATE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Anticoagulant: binds to antithrombin III, enhancing its inhibition of factor Xa and thrombin; also inactivates factors IX, XI, XII, and plasmin.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Continuous IV infusion: 12-18 units/kg/hour, adjusted based on aPTT. Initial bolus of 60-80 units/kg may be given. Typical infusion rate for prophylaxis: 5,000 units subcutaneously every 8-12 hours.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
None Documented
None Documented
Terminal half-life: 1.5-2.5 hours (mean 1.7 h) for IV heparin; dose-dependent, increasing with higher doses (saturable clearance). In patients with renal impairment, half-life prolonged (up to 2-3 times).
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Renal: 50-60% as unchanged drug via urine; reticuloendothelial system: significant hepatic and splenic uptake with depolymerization; biliary: minor. Total clearance is dose-dependent due to saturable cellular binding.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Category A/B
Category C
Electrolyte
Electrolyte